Fragmentation of SIV-gag Vaccine Induces Broader T Cell Responses

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Benlahrech, Adel ^a   Meiser, Andrea ^a   Herath, Shanthi ^a   Papagatsias, Timos ^a   Athanasopoulos, Takis ^b   Li, Fucheng ^c   Self, Steve ^c   Bachy, Veronique ^d   Hervouet, Catherine ^d   Logan, Karen ^e,f   Klavinskis, Linda ^d   Dickson, George ^b   Patterson, Steven ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c USA   (United States)

^d GUY S HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Emergent Biosolutions   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; PROTEASOME; SIMIAN IMMUNODEFICIENCY VIRUS GAG VACCINE; UBIQUITIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MOLECULAR CLONING; PHENOTYPE; TRANSGENE; UBIQUITINATION;

CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; GENE PRODUCTS, GAG; HIV INFECTIONS; HUMANS; PEPTIDE FRAGMENTS; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; RNA STABILITY; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; UBIQUITINATION; VIRAL VACCINES;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84868265708     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048038     Document Type: Article

References (51)

1. Freel SA, Saunders KO, Tomaras GD, (2011) CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunol Res 49: 135-146 doi:10.1007/s12026-010-8177-7.
2. Makedonas G, Betts MR, (2011) Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 239: 109-124 doi:10.1111/j.1600-065X.2010.00968.x.
3. Walker CM, Moody DJ, Stites DP, Levy JA, (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: 1563-1566.
4. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189: 991-998.
5. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860.
6. Matano T, Shibata R, Siemon C, Connors M, Lane HC, et al. (1998) Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72: 164-169.
7. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551-1557 pii: science.1195271; doi:10.1126/science.1195271.
8. Frater AJ, Brown H, Oxenius A, Gunthard HF, Hirschel B, et al. (2007) Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol 81: 6742-6751 pii: JVI.00022-07; doi:10.1128/JVI.00022-07.
9. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3: 205-211.
10. Ferrando-Martinez S, Casazza JP, Leal M, Machmach K, Munoz-Fernandez MA, et al. (2012) Differential gag-specific polyfunctional T cell maturation patterns in HIV-1 Elite Controllers. J Virol pii: JVI.07034-11; doi:10.1128/JVI.07034-11.
11. Richmond M, McKinnon LR, Kiazyk SA, Wachihi C, Kimani M, et al. (2011) Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol 85: 1275-1286 pii: JVI.01707-10; doi:10.1128/JVI.01707-10.
12. Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, et al. (2008) Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol 15: 1745-1748 pii: CVI.00247-08; doi:10.1128/CVI.00247-08.
13. Koup RA, Douek DC, (2011) Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med 1: a007252 pii: a007252; doi:10.1101/cshperspect.a007252.
14. Weidt G, Utermohlen O, Heukeshoven J, Lehmann-Grube F, Deppert W, (1998) Relationship among immunodominance of single CD8+ T cell epitopes, virus load, and kinetics of primary antiviral CTL response. J Immunol 160: 2923-2931.
15. Wallace ME, Keating R, Heath WR, Carbone FR, (1999) The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 73: 7619-7626.
16. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, et al. (2002) Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: 335-339 pii: 415335a; doi:10.1038/415335a.
17. Bullock TN, Mullins DW, Engelhard VH, (2003) Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 170: 1822-1829.
18. Yewdell JW, (2006) Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25: 533-543 pii: S1074-7613(06)00439-0; doi:10.1016/j.immuni.2006.09.005.
19. Im EJ, Hong JP, Roshorm Y, Bridgeman A, Letourneau S, et al. (2011) Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog 7: e1002041 pii: PPATHOGENS-D-10-00557; doi:10.1371/journal.ppat.1002041.
20. Roy-Proulx G, Meunier MC, Lanteigne AM, Brochu S, Perreault C, (2001) Immunodomination results from functional differences between competing CTL. Eur J Immunol 31: 2284-2292 doi:10.1002/1521-4141(200108)31:8<2284::AID-IMMU2284>3.0.CO;2-E.
21. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, et al. (2002) Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168: 4391-4398.
22. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, et al. (2000) T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 192: 1105-1113.
23. Newberg MH, McEvers KJ, Gorgone DA, Lifton MA, Baumeister SH, et al. (2006) Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 176: 319-328 pii: 176/1/319.
24. Kedl RM, Schaefer BC, Kappler JW, Marrack P, (2002) T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 3: 27-32 pii: ni742; doi:10.1038/ni742.
25. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106 nm1461 [pii];10.1038/nm1461 [doi].
26. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16: 319-323 nm.2089 [pii];10.1038/nm.2089 [doi].
27. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, et al. (2010) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 16: 324-328 nm.2108 [pii];10.1038/nm.2108 [doi].
28. Stack JH, Whitney M, Rodems SM, Pollok BA, (2000) A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol 18: 1298-1302 10.1038/82422 [doi].
29. Tobery T, Siliciano RF, (1999) Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 162: 639-642.
30. Tobery TW, Siliciano RF, (1997) Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 185: 909-920.
31. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, et al. (1988) Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 168: 1211-1224.
32. Rodriguez F, An LL, Harkins S, Zhang J, Yokoyama M, et al. (1998) DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 72: 5174-5181.
33. Goldwich A, Hahn SS, Schreiber S, Meier S, Kampgen E, et al. (2008) Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation. J Immunol 180: 372-382 pii: 180/1/372.
34. Singh RA, Barry MA, (2004) Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J Immunol 173: 4387-4393 pii: 173/7/4387.
35. Liu Y, Li F, Liu Y, Hong K, Meng X, et al. (2011) HIV fragment gag vaccine induces broader T cell response in mice. Vaccine 29: 2582-2589 pii: S0264-410X(11)00088-0; doi:10.1016/j.vaccine.2011.01.049.
36. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, et al. (1996) Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 157: 3039-3045.
37. Colleton BA, Huang XL, Melhem NM, Fan Z, Borowski L, et al. (2009) Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells. J Virol 83: 6288-6299 pii: JVI.02611-08; doi:10.1128/JVI.02611-08.
38. Huang XL, Fan Z, Borowski L, Mailliard RB, Rolland M, et al. (2010) Dendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapy. PLoS One 5: e12936 doi:10.1371/journal.pone.0012936.
39. Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR, (2010) Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 5: e9852 doi:10.1371/journal.pone.0009852.
40. Sallusto F, Lanzavecchia A, (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
41. Tsai V, Kawashima I, Keogh E, Daly K, Sette A, et al. (1998) In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 18: 65-75.
42. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106: 19940-19945 pii: 0907898106; doi:10.1073/pnas.0907898106.
43. Sallusto F, Geginat J, Lanzavecchia A, (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763 doi:10.1146/annurev.immunol.22.012703.104702.
44. Dobano C, Rogers WO, Gowda K, Doolan DL, (2007) Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunol Lett 111: 92-102 pii: S0165-2478(07)00120-4; doi:10.1016/j.imlet.2007.05.007.
45. Fluet ME, Whitmore AC, Moshkoff DA, Fu K, Tang Y, et al. (2008) Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine. Virology 370: 22-32 pii: S0042-6822(07)00555-7; doi:10.1016/j.virol.2007.08.020.
46. Wong SB, Buck CB, Shen X, Siliciano RF, (2004) An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J Immunol 173: 3073-3083 pii: 173/5/3073.
47. Sijts EJ, Kloetzel PM, (2011) The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci 68: 1491-1502 doi:10.1007/s00018-011-0657-y.
48. Decaluwe H, Taillardet M, Corcuff E, Munitic I, Law HK, et al. (2010) Gamma(c) deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors. Proc Natl Acad Sci U S A 107: 9311-9316 pii: 0913729107; doi:10.1073/pnas.0913729107.
49. Grant EP, Michalek MT, Goldberg AL, Rock KL, (1995) Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol 155: 3750-3758.
50. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN, (1996) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565-571 pii: S1074-7613(00)80483-5.
51. Slota M, Lim JB, Dang Y, Disis ML, (2011) ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 10: 299-306 doi:10.1586/erv.10.169.